BioInvent Q2 2025: Narrowed Focus on BI-1206 and BI-1808 - Redeye

Redeye comments on BioInvent’s Q2 report 2025. New positive results with BI-1206 in solid tumours and Non-Hodgkin lymphoma and with BI-1808 in T-cell lymphoma were presented. A pause of BI-1607 and BI-1910 was announced yesterday as the company focuses on late- to mid-stage development of BI-1206 and BI-1808.

Länk till analysen i sin helhet: https://www.redeye.se/research/1125451/bioinvent-q2-2025-narrowed-focus-on-bi-1206-and-bi-1808?utm_source=finwire&utm_medium=RSS